These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30345152)

  • 21. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.
    Greuter T; Malhi H; Gores GJ; Shah VH
    JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis.
    Kim J; Lee SK; Jeong SY; Cho HJ; Park J; Kim TM; Kim S
    J Nanobiotechnology; 2021 Nov; 19(1):372. PubMed ID: 34789265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis.
    Garcia-Martinez I; Alen R; Rada P; Valverde AM
    Front Med (Lausanne); 2020; 7():395. PubMed ID: 32850903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Ibrahim SH; Hirsova P; Gores GJ
    Gut; 2018 May; 67(5):963-972. PubMed ID: 29367207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
    Jia Y; French B; Tillman B; French S
    Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA; Loomba R
    J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers.
    Wang Q; Tang X; Wang Y; Zhang D; Li X; Liu S
    J Adv Res; 2024 Mar; ():. PubMed ID: 38494073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease.
    Newman LA; Useckaite Z; Johnson J; Sorich MJ; Hopkins AM; Rowland A
    Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V; Morgan TR
    Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences.
    Joshi-Barve S; Kirpich I; Cave MC; Marsano LS; McClain CJ
    Cell Mol Gastroenterol Hepatol; 2015 Jul; 1(4):356-367. PubMed ID: 28210688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.